PURPOSE: We have previously shown that a “short-term, low-dose” treatment approach with statins, angiotensin receptor blockers, and especially their low-dose combination, is effective in improving arterial wall properties in apparently healthy middle-age men. This study was performed to expand investigation of its effects on inflammation and oxidative stress.
METHODS: The study was performed supplementary to 3 previous studies, overall 65 treated participants (25 received fluvastatin 10 mg, 20 valsartan 20 mg, 20 their combination) and 65 participants placebo. The stored blood samples (collected at inclusion and after 30 days of treatment) were used to measure high-sensitivity CRP, interleukin-6, vascular cell adhesion molecule-1, total antioxidant status, glutathione peroxidase, and selenium concentration.
RESULTS: A low-dose combination decreased inflammation parameters (high-sensitivity CRP: from 1.2 ± 0.1 to 0.7 ± 0.1 mg/L; P < .001; vascular cell adhesion molecule-1: from 523 ± 21 to 482 ± 12 pg/mL; P < .05; while interleukin-6 did not reach the level of significance). It also increased antioxidant defenses, as measured by total antioxidant status and glutathione peroxidase (from 1.4 ± 0.04 to 1.5 ± 0.04 mmol/L; P < .01, and from 1.2 ± 0.06 to 1.4 ± 0.06 μkat/g hemoglobin; P < .05, respectively), accompanied by decreased selenium levels. Low-dose valsartan was separately less effective than the combination. No changes were observed in the control groups.
CONCLUSIONS: Low-dose combination of fluvastatin and valsartan and, to a lesser extent low-dose valsartan alone, produced important anti-inflammatory and anti-oxidative effects. These results confirm and extend the potential of the “short-term, low-dose” preventive strategy.
To expand a “short-term, low-dose” treatment approach, parameters of inflammation and oxidative stress were measured in blood samples of treated and control participants. A low-dose combination of fluvastatin and valsartan produced anti-inflammatory and anti-oxidative results. Results confirm the effectiveness of a new preventive strategy.
Department of Vascular Diseases (Drs Janic[Combining Acute Accent], Lunder, and Šabovicč) and Clinical Institute of Clinical Chemistry and Biochemistry (Dr Prezelj), University of Ljubljana Medical Centre, Ljubljana, Slovenia.
Correspondence: Miodrag Janic[Combining Acute Accent], MD, Department of Vascular Diseases, University of Ljubljana Medical Centre, Zaloška cesta 7, 1000 Ljubljana, Slovenia (email@example.com).
The authors declare no conflicts of interest.